We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
INVESTORS & MEDIA
INVESTOR OVERVIEW
There are currently no events to display.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006 South San Francisco, CA, January 24, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report fourth quarter and year end 2005 financial results on Tuesday, January 31, 2006 at 4:00
SOUTH SAN FRANCISCO, CA, Sep 08, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional Phase I clinical trial data relating to omecamtiv mecarbil (formerly CK-1827452) is scheduled to be presented as a poster presentation at the 2010 Heart Failure
Cytokinetics Will Receive $25 Million Plus Potential Milestone Payments and Royalties THOUSAND OAKS, Calif. AND SOUTH SAN FRANCISCO, Calif, (June 12, 2013) - Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced an expansion of their strategic collaboration to include
First Chronic Dosing Trial of Oral Omecamtiv Mecarbil Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function and Volumes THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2015 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics